Fate Therapeutics Inc (NASDAQ: FATE) on Tuesday, plunged -4.67% from the previous trading day, before settling in for the closing price of $1.07. Within the past 52 weeks, FATE’s price has moved between $0.66 and $1.94.
A company in the Healthcare sector has dropped its sales by -2.63% annually for the last half of the decade. The company achieved an average annual earnings per share of 29.82%. With a float of $109.75 million, this company’s outstanding shares have now reached $115.34 million.
Fate Therapeutics Inc (FATE) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Fate Therapeutics Inc is 4.85%, while institutional ownership is 71.34%. The most recent insider transaction that took place on Jan 09 ’26, was worth 11,275. In this transaction an insider of this company sold 10,589 shares at a rate of $1.06, taking the stock ownership to the 387,081 shares. Before that another transaction happened on Jan 09 ’26, when Company’s President and CEO sold 5,190 for $1.07, making the entire transaction worth $5,557. This insider now owns 329,708 shares in total.
Fate Therapeutics Inc (FATE) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.44 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.42) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.87% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Fate Therapeutics Inc (FATE) is currently performing well based on its current performance indicators. A quick ratio of 7.87 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.32, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -1.16 in one year’s time.
